Views & Analysis Digital health round-up: online tool raises awareness of RA ... Richard Staines gives a round-up of the latest developments in digital health.
News Payday for AbbVie as Humira biosimilar delayed for five year... Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
News FDA rejects J&J's sirukumab RA drug The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to evaluate its safety.
News Roche under pressure as second rituximab biosimilar filed in... Sandoz is following closely behind rival from Teva and Celltrion.
News Ready to pounce: Samsung joins Amgen with Humira biosimilar ... No-one can launch biosimilars until patent expires next year
News FDA advisers reject J&J rheumatoid arthritis drug Expert panel concerned about safety of sirukumab.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
